Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Agenus Inc. - Common Stock (NQ:AGEN)

6.120 +2.770 (+82.69%)
Official Closing Price Updated: 4:15 PM EDT, Jul 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Agenus Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
Discover the most active stocks in Monday's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session. The market value of their outstanding shares is at $139.5 million. Q32 Bio (NASDAQ:QTTB) stock rose... 
Via Benzinga
Top stock movements in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing ↗
Agenus (NASDAQ:AGEN) said it is shifting its development focus and financial resources toward a Phase 3 registrational trial of neoadjuvant botensilimab plus balstilimab, known as BOT/BAL, in high-risk... 
Via MarketBeat
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
From Agenus Inc.
Via Business Wire
News headline image
Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Annual Meeting: BOT/BAL Leads Cancer Drug Push as Balance Sheet Improves ↗
Agenus (NASDAQ:AGEN) told shareholders at its 2026 virtual annual meeting that it remains focused on advancing its botensilimab and balstilimab immunotherapy combination, known as BOT/BAL, while... 
Via MarketBeat
News headline image
Agenus Announces Virtual 2026 Annual Shareholders Meeting
From Agenus Inc.
Via Business Wire
News headline image
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
From Agenus Inc.
Via Business Wire
News headline image
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
From Agenus Bio
Via Business Wire
News headline image
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
From Agenus Inc. & BAP Pharma
Via Business Wire
News headline image
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access
From Agenus Inc.
Via Business Wire
News headline image
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
From Agenus Bio
Via Business Wire
News headline image
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
From Agenus Inc.
Via Business Wire
News headline image
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
From Agenus Inc.
Via Business Wire
News headline image
Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update
From Agenus Bio
Via Business Wire
News headline image
Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL
From Agenus Bio
Via Business Wire
News headline image
Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors
From Agenus Bio
Via Business Wire
News headline image
Agenus (AGEN) Q2 2025 Earnings Call Transcript ↗
Agenus (AGEN) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.